May 24, 2021 10:33 AM EDTUpdated 06:57 PM

Verastem wins breakthrough nod for combo therapy in ovarian cancer; EMA picks up speedy review of BioMarin's gene therapy

Kyle Blankenship

Max Gelman

Senior Editor

Verastem has earned the FDA’s breakthrough therapy designation for its novel RAF/MEK inhibitor VS-6766 as a combo therapy with in-house FAK inhibitor defactinib to treat …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Verastem wins breakthrough nod for combo therapy in ovarian cancer; EMA picks up speedy review of BioMarin's gene therapy

Kyle Blankenship

Max Gelman

Senior Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Ve­rastem wins break­through nod for com­bo ther­a­py in ovar­i­an can­cer; EMA picks up speedy re­view of Bio­Mar­in's gene ther­a­py

Senior Editor

Sign up to read this article for free.

Verastem wins breakthrough nod for combo therapy in ovarian cancer; EMA picks up speedy review of BioMarin's gene therapy